NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Get Started
$124.05 +0.07 (+0.06 %)
(As of 02/21/2019 09:49 AM ET)
Previous Close$123.98
Today's Range$123.63 - $124.18
52-Week Range$96.99 - $134.55
Volume60,446 shs
Average Volume1.31 million shs
Market Capitalization$25.30 billion
P/E Ratio16.24
Dividend Yield0.78%
Beta1.16
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ZBH
Previous SymbolNYSE:ZMH
CUSIPN/A
Webwww.zimmerbiomet.com
Phone574-267-6131

Debt

Debt-to-Equity Ratio0.75
Current Ratio1.85
Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio16.24
Forward P/E Ratio15.86
P/E Growth2.22

Sales & Book Value

Annual Sales$7.93 billion
Price / Sales3.19
Cash Flow$17.6458 per share
Price / Cash Flow7.03
Book Value$55.28 per share
Price / Book2.24

Profitability

EPS (Most Recent Fiscal Year)$7.64
Net Income$-379,200,000.00
Net Margins-4.78%
Return on Equity13.17%
Return on Assets6.13%

Miscellaneous

Employees18,200
Outstanding Shares203,980,000
Market Cap$25.30 billion
OptionableOptionable

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Wednesday, December 12th. Investors of record on Friday, December 28th will be paid a dividend of $0.24 per share on Thursday, January 31st. This represents a $0.96 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Thursday, December 27th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) issued its quarterly earnings results on Friday, February, 1st. The medical equipment provider reported $2.18 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $2.18. The medical equipment provider had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a positive return on equity of 13.17% and a negative net margin of 4.78%. Zimmer Biomet's quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.10 EPS. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY19 earnings guidance on Friday, February, 1st. The company provided earnings per share (EPS) guidance of $7.70-7.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.81. The company issued revenue guidance of $7.89-7.97 billion (+/- 0.5%), compared to the consensus revenue estimate of $7.96 billion.Zimmer Biomet also updated its FY 2019 guidance to $7.70-7.90 EPS.

What price target have analysts set for ZBH?

23 equities research analysts have issued 12 month target prices for Zimmer Biomet's shares. Their forecasts range from $96.00 to $150.00. On average, they anticipate Zimmer Biomet's share price to reach $127.5238 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 3 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "Over the past three months, Zimmer Biomet has underperformed its industry. We are concerned about the company's escalating costs and expenses that are exerting considerable pressure on the bottom line. Also, declining dental sales at CER is a drag. Adverse currency movements continue to remain a major headwind for the company. However, post a mixed third quarter by Zimmer Biomet, we are hopeful about the company’s consistent efforts in product and renovation through research and development. Improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet reported strong top-line numbers within its S.E.T arm." (1/12/2019)
  • 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
  • 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
  • 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)

Has Zimmer Biomet been receiving favorable news coverage?

Media headlines about ZBH stock have trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zimmer Biomet earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Zimmer Biomet's key competitors?

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP, CFO & Interim Chief Accounting Officer (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.83%), Massachusetts Financial Services Co. MA (6.66%), Longview Partners Guernsey LTD (3.16%), Nordea Investment Management AB (1.84%), Northern Trust Corp (1.76%) and Geode Capital Management LLC (1.30%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, David C Dvorak, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., Harris Associates L P, Wedge Capital Management L L P NC, Longview Partners Guernsey LTD, Nuveen Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, D. E. Shaw & Co. Inc., Ceredex Value Advisors LLC, Factory Mutual Insurance Co., Geode Capital Management LLC, Prudential Financial Inc., BlackRock Inc. and State of Tennessee Treasury Department. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell and Michael W Michelson. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $123.98.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $25.29 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  661 (Vote Outperform)
Underperform Votes:  553 (Vote Underperform)
Total Votes:  1,214
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: Why Net Income is Important to Investors
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel